Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells

Zoltán H. Németh, Hector R. Wong, Kelli Odoms, Edwin A. Deitch, Csaba Szabo, E. Sylvester Vizi, György Haskó

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The transcription factor nuclear factor κB (NF-κB) is activated and seems to promote oncogenesis in certain cancers. A major mechanism of NF-κB activation in cells involves cytoplasm-to-nucleus translocation of this transcription factor after hydrolysis of the cytoplasmic inhibitor inhibitory κB (IκB) by the 26S proteasome. Because selective proteasome inhibitors have been shown to block IκB degradation; consequently, NF-κB activation in a variety of cellular systems, proteasome inhibitors were proposed as potential therapeutic agents for the treatment of cancer. However, under certain conditions, IκB degradation and NF-κB activation are not mediated by the proteasome system. We investigated how proteasome inhibitors affected NF-κB activation in the intestinal epithelial cancer cell line HT-29, which has been documented to have an atypical NF-κB regulation. Treatment of cells with the selective proteasome inhibitors carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal (MG-115), carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), or lactacystin induced NF-κB activation as indicated by both an increase in NF-κB DNA binding and transcriptional activity. This increase in NF-κB activation caused by proteasome inhibitors was accompanied by an increase in IκB kinase activation and a degradation of IκBα but not IκBβ. Furthermore, proteasome inhibitors induced the expression of NF-κB target genes. In summary, these results demonstrate a unique effect of proteasome inhibitors on the IκB-NF-κB systems in HT-29 cells, in which proteasome inhibitors activate rather than deactivate the NF-κB system. We conclude that the use of proteasome inhibitors to block NF-κB activation in cancer cells may not always be a viable approach.

Original languageEnglish (US)
Pages (from-to)342-349
Number of pages8
JournalMolecular Pharmacology
Volume65
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

HT29 Cells
Proteasome Inhibitors
Phosphotransferases
Transcription Factors
Intestinal Neoplasms
Neoplasms
Proteasome Endopeptidase Complex
Carcinogenesis
Cytoplasm
Hydrolysis
Epithelial Cells
Cell Line

ASJC Scopus subject areas

  • Pharmacology

Cite this

Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells. / Németh, Zoltán H.; Wong, Hector R.; Odoms, Kelli; Deitch, Edwin A.; Szabo, Csaba; Vizi, E. Sylvester; Haskó, György.

In: Molecular Pharmacology, Vol. 65, No. 2, 02.2004, p. 342-349.

Research output: Contribution to journalArticle

Németh, Zoltán H. ; Wong, Hector R. ; Odoms, Kelli ; Deitch, Edwin A. ; Szabo, Csaba ; Vizi, E. Sylvester ; Haskó, György. / Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells. In: Molecular Pharmacology. 2004 ; Vol. 65, No. 2. pp. 342-349.
@article{8dbd8c8ef6304172b2e487c6eb445226,
title = "Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells",
abstract = "The transcription factor nuclear factor κB (NF-κB) is activated and seems to promote oncogenesis in certain cancers. A major mechanism of NF-κB activation in cells involves cytoplasm-to-nucleus translocation of this transcription factor after hydrolysis of the cytoplasmic inhibitor inhibitory κB (IκB) by the 26S proteasome. Because selective proteasome inhibitors have been shown to block IκB degradation; consequently, NF-κB activation in a variety of cellular systems, proteasome inhibitors were proposed as potential therapeutic agents for the treatment of cancer. However, under certain conditions, IκB degradation and NF-κB activation are not mediated by the proteasome system. We investigated how proteasome inhibitors affected NF-κB activation in the intestinal epithelial cancer cell line HT-29, which has been documented to have an atypical NF-κB regulation. Treatment of cells with the selective proteasome inhibitors carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal (MG-115), carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), or lactacystin induced NF-κB activation as indicated by both an increase in NF-κB DNA binding and transcriptional activity. This increase in NF-κB activation caused by proteasome inhibitors was accompanied by an increase in IκB kinase activation and a degradation of IκBα but not IκBβ. Furthermore, proteasome inhibitors induced the expression of NF-κB target genes. In summary, these results demonstrate a unique effect of proteasome inhibitors on the IκB-NF-κB systems in HT-29 cells, in which proteasome inhibitors activate rather than deactivate the NF-κB system. We conclude that the use of proteasome inhibitors to block NF-κB activation in cancer cells may not always be a viable approach.",
author = "N{\'e}meth, {Zolt{\'a}n H.} and Wong, {Hector R.} and Kelli Odoms and Deitch, {Edwin A.} and Csaba Szabo and Vizi, {E. Sylvester} and Gy{\"o}rgy Hask{\'o}",
year = "2004",
month = "2",
doi = "10.1124/mol.65.2.342",
language = "English (US)",
volume = "65",
pages = "342--349",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells

AU - Németh, Zoltán H.

AU - Wong, Hector R.

AU - Odoms, Kelli

AU - Deitch, Edwin A.

AU - Szabo, Csaba

AU - Vizi, E. Sylvester

AU - Haskó, György

PY - 2004/2

Y1 - 2004/2

N2 - The transcription factor nuclear factor κB (NF-κB) is activated and seems to promote oncogenesis in certain cancers. A major mechanism of NF-κB activation in cells involves cytoplasm-to-nucleus translocation of this transcription factor after hydrolysis of the cytoplasmic inhibitor inhibitory κB (IκB) by the 26S proteasome. Because selective proteasome inhibitors have been shown to block IκB degradation; consequently, NF-κB activation in a variety of cellular systems, proteasome inhibitors were proposed as potential therapeutic agents for the treatment of cancer. However, under certain conditions, IκB degradation and NF-κB activation are not mediated by the proteasome system. We investigated how proteasome inhibitors affected NF-κB activation in the intestinal epithelial cancer cell line HT-29, which has been documented to have an atypical NF-κB regulation. Treatment of cells with the selective proteasome inhibitors carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal (MG-115), carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), or lactacystin induced NF-κB activation as indicated by both an increase in NF-κB DNA binding and transcriptional activity. This increase in NF-κB activation caused by proteasome inhibitors was accompanied by an increase in IκB kinase activation and a degradation of IκBα but not IκBβ. Furthermore, proteasome inhibitors induced the expression of NF-κB target genes. In summary, these results demonstrate a unique effect of proteasome inhibitors on the IκB-NF-κB systems in HT-29 cells, in which proteasome inhibitors activate rather than deactivate the NF-κB system. We conclude that the use of proteasome inhibitors to block NF-κB activation in cancer cells may not always be a viable approach.

AB - The transcription factor nuclear factor κB (NF-κB) is activated and seems to promote oncogenesis in certain cancers. A major mechanism of NF-κB activation in cells involves cytoplasm-to-nucleus translocation of this transcription factor after hydrolysis of the cytoplasmic inhibitor inhibitory κB (IκB) by the 26S proteasome. Because selective proteasome inhibitors have been shown to block IκB degradation; consequently, NF-κB activation in a variety of cellular systems, proteasome inhibitors were proposed as potential therapeutic agents for the treatment of cancer. However, under certain conditions, IκB degradation and NF-κB activation are not mediated by the proteasome system. We investigated how proteasome inhibitors affected NF-κB activation in the intestinal epithelial cancer cell line HT-29, which has been documented to have an atypical NF-κB regulation. Treatment of cells with the selective proteasome inhibitors carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal (MG-115), carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), or lactacystin induced NF-κB activation as indicated by both an increase in NF-κB DNA binding and transcriptional activity. This increase in NF-κB activation caused by proteasome inhibitors was accompanied by an increase in IκB kinase activation and a degradation of IκBα but not IκBβ. Furthermore, proteasome inhibitors induced the expression of NF-κB target genes. In summary, these results demonstrate a unique effect of proteasome inhibitors on the IκB-NF-κB systems in HT-29 cells, in which proteasome inhibitors activate rather than deactivate the NF-κB system. We conclude that the use of proteasome inhibitors to block NF-κB activation in cancer cells may not always be a viable approach.

UR - http://www.scopus.com/inward/record.url?scp=1642538959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642538959&partnerID=8YFLogxK

U2 - 10.1124/mol.65.2.342

DO - 10.1124/mol.65.2.342

M3 - Article

C2 - 14742676

AN - SCOPUS:1642538959

VL - 65

SP - 342

EP - 349

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -